Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Deconinck

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Translational Psychiatry|February 19, 2020
ADHD and ASD: distinct brain patterns of inhibition-related activation?Ariadna Albajara Sáenz, Mathilde Septier, Peter Van Schuerbeek, et al.
The Lancet. Neurology|September 18, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Francesco Muntoni, Giovanni Baranello, et al.
Neuromuscular Disorders : NMD|March 4, 2014
Diagnostic approach to the congenital muscular dystrophiesCarsten G Bönnemann, Ching H Wang, Susana Quijano-Roy, et al.
The Journal of Infectious Diseases|August 23, 2025
Genetic landscape of a cohort of children with varicella-zoster virus encephalitis, cerebellitis and strokeFranziska Winzig, Kerstin De Keukeleere, Esther Bartholomeus, et al.
The New England Journal of Medicine|February 24, 2021
Risdiplam in Type 1 Spinal Muscular AtrophyGiovanni Baranello, Basil T Darras, John W Day, et al.
Journal of Neuromuscular Diseases|March 14, 2026
Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPICharlotte Colot, Federica Trucco, Pablo Ruiz Chicaiza, et al.
Brain : a Journal of Neurology|November 26, 2013
Natural history of pulmonary function in collagen VI-related myopathiesA Reghan Foley, Susana Quijano-Roy, James Collins, et al.
The Lancet. Neurology|September 12, 2014
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 studyThomas Voit, Haluk Topaloglu, Volker Straub, et al.
Human Genomics|March 1, 2023
Congenital hydrocephalus: new Mendelian mutations and evidence for oligogenic inheritanceValerie Jacquemin, Nassim Versbraegen, Sarah Duerinckx, et al.
Journal of Neurology|February 3, 2023
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)Maryam Oskoui, John W Day, Nicolas Deconinck, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Translational Psychiatry|February 19, 2020
ADHD and ASD: distinct brain patterns of inhibition-related activation?Ariadna Albajara Sáenz, Mathilde Septier, Peter Van Schuerbeek, et al.
The Lancet. Neurology|September 18, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Francesco Muntoni, Giovanni Baranello, et al.
Neuromuscular Disorders : NMD|March 4, 2014
Diagnostic approach to the congenital muscular dystrophiesCarsten G Bönnemann, Ching H Wang, Susana Quijano-Roy, et al.
The Journal of Infectious Diseases|August 23, 2025
Genetic landscape of a cohort of children with varicella-zoster virus encephalitis, cerebellitis and strokeFranziska Winzig, Kerstin De Keukeleere, Esther Bartholomeus, et al.
The New England Journal of Medicine|February 24, 2021
Risdiplam in Type 1 Spinal Muscular AtrophyGiovanni Baranello, Basil T Darras, John W Day, et al.
Journal of Neuromuscular Diseases|March 14, 2026
Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPICharlotte Colot, Federica Trucco, Pablo Ruiz Chicaiza, et al.
Brain : a Journal of Neurology|November 26, 2013
Natural history of pulmonary function in collagen VI-related myopathiesA Reghan Foley, Susana Quijano-Roy, James Collins, et al.
The Lancet. Neurology|September 12, 2014
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 studyThomas Voit, Haluk Topaloglu, Volker Straub, et al.
Human Genomics|March 1, 2023
Congenital hydrocephalus: new Mendelian mutations and evidence for oligogenic inheritanceValerie Jacquemin, Nassim Versbraegen, Sarah Duerinckx, et al.
Journal of Neurology|February 3, 2023
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)Maryam Oskoui, John W Day, Nicolas Deconinck, et al.
Pageof 8